Inclusion criteria:

• 18 years old and above, male or female
• Diagnosed by trained clinical doctors as postherpetic neuralgia, which is an indication for peripheral nerve stimulation therapy;
• Assess the damage or disease of the peripheral sensory system through the four questions of Douleur Neuropathy before surgery;
• The subject has received conventional treatment but the efficacy is poor, or cannot tolerate the side effects of conventional treatment;
• Visual analogue scale for pain within 24 hours before surgery ≥ 5;
• The subjects are able to understand the purpose of this study, have sufficient compliance with the research treatment, and are willing to sign an informed consent form;

Exclusion criteria:

• Subjects who need to receive both radio frequency modulation and intrathecal drug infusion treatment simultaneously;
• Subjects who are known to have cardiac implants (pacemakers or defibrillators) or other implantable neural stimulators (spinal cord stimulators or deep brain stimulators, etc.);
• Subjects with severe psychological and/or mental disorders and/or non therapeutic drug dependence;
• Subjects expected to undergo MRI examination within 30 days after PNS implantation;
• Expected to be discharged within 48 hours or less;
• Target nerve damage or muscle defects in known pain areas;
• Subjects who are known to be allergic to skin contact materials (tape or adhesive);
• Allergy to anesthetics such as lidocaine;
• Concomitant severe heart disease, liver disease, kidney disease, respiratory system disease, and coagulation dysfunction;
• Pregnant women, lactating women, or women planning to have children within the next three months;
• Subjects who have participated in any other clinical trial, or who may participate in any other trial after enrollment;
• Other situations that the researcher deems unsuitable for participation in this clinical trial